Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 6/2012

01-06-2012 | Reply

Reply

Author: S. M. Hadi

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2012

Login to get access

Excerpt

The article by Ullah et al. [1] published by us followed from the paper of Levine and co-workers [2], wherein these authors had expressed their inability to explain the molecular basis for the relative resistance of normal cells to the cytotoxic action of ascorbic acid. Our results are actually in support of the results of Levine and his group. However, they are an attempt to explain one of the aspects of the results of these authors. Therefore, as mentioned in the letter submitted by Rodemeister et al., the question of not supporting the results of Chen et al. [2] does not arise. Although we realize that we have not used tumor cells in our study, such work has already been done by Levine and his group and many other workers as mentioned in our paper. In the discussion of our paper, we say that based on our results with normal cells and the results of various other groups, it is our ‘belief’ that the preferential cytotoxic action of ascorbic acid against cancer cells is explained by the ability of ascorbic acid to mobilize endogenous copper ions. In support of our idea, we have also given several lines of indirect evidence in literature. …
Literature
1.
go back to reference Ullah MF, Khan HY, Zubair H, Shamim U, Hadi SM (2011) The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: implications for chemotherapeutic action against cancer. Cancer Chemother Pharmacol 67:103–110PubMedCrossRef Ullah MF, Khan HY, Zubair H, Shamim U, Hadi SM (2011) The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: implications for chemotherapeutic action against cancer. Cancer Chemother Pharmacol 67:103–110PubMedCrossRef
2.
go back to reference Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M (2008) Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 105:11105–11109PubMedCrossRef Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M (2008) Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 105:11105–11109PubMedCrossRef
3.
go back to reference Wilms LC, Claughton TA, de Kok TM, Kleinjans JC (2007) GSTM1 and GSTT1 polymorphism influences protection against induced oxidative DNA damage by quercetin and ascorbic acid in human lymphocytes in vitro. Food Chem Toxicol 45:2592–2596PubMedCrossRef Wilms LC, Claughton TA, de Kok TM, Kleinjans JC (2007) GSTM1 and GSTT1 polymorphism influences protection against induced oxidative DNA damage by quercetin and ascorbic acid in human lymphocytes in vitro. Food Chem Toxicol 45:2592–2596PubMedCrossRef
Metadata
Title
Reply
Author
S. M. Hadi
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2012
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-012-1861-7

Other articles of this Issue 6/2012

Cancer Chemotherapy and Pharmacology 6/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine